Mihaela Diana Danca

US Patent:

7442830, Oct 28, 2008

Filed:

Aug 6, 2007

Appl. No.:

11/890412

Inventors:

Edward J. Olhava - Cambridge MA, US
Mihaela Diana Danca - Mendham NJ, US

Assignee:

Millenium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07F 5/02
C07C 229/00
C07C 233/00
C07C 235/00
C07C 239/00
A61K 31/69

US Classification:

562 7, 562450, 564 8, 564169, 514 64

Abstract:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

US Patent:

7625931, Dec 1, 2009

Filed:

Jan 13, 2006

Appl. No.:

11/331347

Inventors:

Scott A. Mitchell - East Haven CT, US
Mihaela Diana Danca - Mendham NJ, US
Peter A. Blomgren - North Branford CT, US
Robert W. DeSimone - Durham CT, US
Douglas A. I. Pippin - Chester Springs PA, US

Assignee:

CGI Pharmaceuticals, Inc. - Branford CT

International Classification:

A61K 31/4439
C07D 403/02

US Classification:

514341, 5462727, 5462741

Abstract:

Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

US Patent:

7687662, Mar 30, 2010

Filed:

Jul 2, 2008

Appl. No.:

12/217243

Inventors:

Edward J. Olhava - Newton MA, US
Mihaela Diana Danca - Mendham NJ, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07F 5/02
C07C 229/00
C07C 233/00
C07C 235/00
C07C 239/00
A61K 31/69

US Classification:

562 7, 562450, 564 8, 564169, 514 64

Abstract:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

US Patent:

7777040, Aug 17, 2010

Filed:

May 2, 2006

Appl. No.:

11/415419

Inventors:

Scott A. Mitchell - East Haven CT, US
Mihaela Diana Danca - Mendham NJ, US
Peter A. Blomgren - North Branford CT, US
David R. Brittelli - Branford CT, US
Pavel Zhichkin - Latham NY, US
Matthew E. Voss - Nassau NY, US

Assignee:

CGI Pharmaceuticals, Inc. - Branford CT

International Classification:

C07D 215/38

US Classification:

546167

Abstract:

Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

US Patent:

7790719, Sep 7, 2010

Filed:

Jul 26, 2007

Appl. No.:

11/878708

Inventors:

Tricia J. Vos - Medford MA, US
Michael Patane - Andover MA, US
Michael E. Solomon - Concord MA, US
Christopher Blackburn - Natick MA, US
Mihaela D. Danca - Belmont MA, US

Assignee:

Ore Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31/505
A61K 31/535
A61K 31/517
A61K 31/445
C07D 239/02
C07D 233/88
C07D 413/14
C07D 239/70

US Classification:

5142358, 544332, 544122, 544253, 5483325, 546210, 514275, 5142581, 514326, 514398

Abstract:

This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I:.

US Patent:

7838673, Nov 23, 2010

Filed:

Oct 16, 2007

Appl. No.:

11/974758

Inventors:

Edward J. Olhava - Cambridge MA, US
Mihaela Diana Danca - Mendham NJ, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07F 5/04
A61K 31/69

US Classification:

544229, 544349, 544406, 564 8, 564155, 560 29, 514 64, 514249, 5142521

Abstract:

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

US Patent:

7932248, Apr 26, 2011

Filed:

Nov 9, 2006

Appl. No.:

11/594993

Inventors:

Richard Schumacher - Monroe NY, US
Jianguo Ma - Natick MA, US
Brian Herbert - Stockholm NJ, US
Mihaela Diana Danca - Mendham NJ, US
Wenge Xie - Mahwah NJ, US
Truc Minh Nguyen - New York NY, US
Ashok Tehim - Ridgewood NJ, US

Assignee:

Memory Pharmaceuticals Corporation - Montvale NJ

International Classification:

A61P 25/28
A61K 31/551
C07D 487/08

US Classification:

514219, 514221, 540556

Abstract:

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

US Patent:

7365070, Apr 29, 2008

Filed:

Dec 4, 2003

Appl. No.:

10/727997

Inventors:

Tricia J. Vos - Medford MA, US
Michael Patane - Andover MA, US
Michael E. Solomon - Concord MA, US
Christopher Blackburn - Natick MA, US
Mihaela D. Danca - Belmont MA, US

Assignee:

Ore Pharmaceuticals Inc. - Gaithersburg MD

International Classification:

A61K 31/40
A61K 31/415
A61K 31/381
A61K 31/535
A61K 31/445
C07D 211/26
C07D 207/04
C07D 333/22
C07D 265/30
C07D 233/66
C07D 241/04
C07D 409/12
C07D 221/20

US Classification:

5142385, 51425212, 514278, 514331, 514357, 514399, 514408, 514448, 544169, 544402, 546 16, 546231, 5462804, 5483365, 548569

Abstract:

This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I:.